Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the positron emission tomography (pet) nuclear medicine market?
The positron emission tomography (PET) nuclear medicine market has grown rapidly, expected to increase from $11.49 billion in 2024 to $13.2 billion in 2025 at a CAGR of 14.9%. Growth factors include a rising prevalence of cardiovascular and urological diseases, increasing healthcare expenditures, an aging population, and a growing number of hospitals.
What will be the positron emission tomography (pet) nuclear medicine market size in the future?
The positron emission tomography (PET) nuclear medicine market is expected to witness rapid expansion, reaching $22.71 billion by 2029 at a CAGR of 14.5%, driven by rising investments in research and development, increased preference for minimally invasive diagnostics, growing global healthcare infrastructure, higher demand for food and pharmaceutical packaging, and the rising prevalence of cancer. Key trends include advancements in technology, multi-modality diagnostics, AI integration, digital PET systems, and personalized medicine.
Get your positron emission tomography (pet) nuclear medicine market report here!
What main drivers are fueling expansion in the positron emission tomography (pet) nuclear medicine market?
The increasing prevalence of chronic diseases is expected to propel the growth of the positron emission tomography (PET) nuclear medicine market going forward. A chronic disease is a long-lasting health condition that typically persists for three months or more and may require ongoing medical attention or limit daily activities. The rise in chronic diseases is driven by factors such as an aging population, lack of physical activity, unhealthy eating habits, and environmental risks. PET nuclear medicine assists in managing chronic diseases by offering advanced imaging methods that enable early detection, precise diagnosis, and ongoing monitoring of these illnesses. For instance, in February 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, around 20 million new cancer cases and 9.7 million cancer-related deaths were recorded in 2022. Additionally, by 2050, new cancer cases are expected to exceed 35 million, representing a 77% increase from the 2022 count. Therefore, the increasing prevalence of chronic diseases drives the growth of the positron emission tomography (PET) nuclear medicine market.
What key areas define the segmentation of the global positron emission tomography (pet) nuclear medicine market?
The positron emission tomography (PET) nuclear medicine market covered in this report is segmented –
1) By Type: F-18, Rb-82, Other Types
2) By Procedure: Diagnostic Procedures, Single Photon Emission Computed Tomography Procedures, Positron Emission Tomography Procedures, Therapeutic Procedures, Beta Emitter Procedures, Alpha Emitter Procedures, Brachytherapy Procedures
3) By Application: Oncology, Cardiology, Neurology, Other Applications
4) By End User: Hospitals, Diagnostic Centers, Research Institutes
Subsegments:
1) By F-18 (Fluorine-18): F-18 FDG (Fluorodeoxyglucose), F-18 NaF (Sodium Fluoride), F-18 Fluorocholine
2) By Rb-82 (Rubidium-82): Rb-82 for Myocardial Perfusion Imaging, Rb-82 for Cardiac PET Stress Testing, Rb-82 for Other Cardiac Applications
3) By Other Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Ga-68 (Gallium-68)
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19151&type=smp
Who are the dominant players expanding their reach in the positron emission tomography (pet) nuclear medicine market?
Major companies operating in the positron emission tomography (PET) nuclear medicine marker are Cardinal Health, Bayer AG, Medtronic plc, Siemens Healthineers AG, Fujifilm Holdings Corporation, Stryker Corporation, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Agfa HealthCare NV, Scripps Health, Shimadzu Corporation, Jubilant DraxImage Inc., Neusoft Medical Systems Co. Ltd., Toshiba America Medical Systems Inc., Lantheus Holdings Inc., Advanced Accelerator Applications, Bruker Corporation, Eckert & Ziegler Strahlen- und Medizintechnik AG, Canon Medical Systems Corporation, Digirad Corporation, NorthStar Medical Radioisotopes LLC, Mediso Medical Imaging Systems Ltd.
How are evolving market trends shaping positron emission tomography (pet) nuclear medicine Strategies?
Prominent businesses in the positron emission tomography (PET) nuclear medicine market are focusing on crafting technologically refined products including PET slice scanners that yield high-definition pictures of metabolic operations. Essentially, a PET slice scanner merges positron emission tomography (PET) and sophisticated computing approaches to produce in-depth, sectional visuals of metabolic functions within the body which become instrumental in diagnosing and observing diseases, especially cancer. To serve an illustration, Positron Corporation, a nuclear medicine enterprise based in the US, unveiled the NeuSight PET-CT 3D 64-slice scanner in July 2024. This advanced scanner broadens the boundaries in imaging and diagnostic accuracy, amalgamating cutting-edge technology with patient ease and system efficiency. Specifically designed to revolutionize cardiac PET imaging, this scanner offers unparalleled value and performance at an unrivaled cost, making it perfect for cardiac and cancer research. Offering enhanced data capture and progressive identification technology, the NeuSight PET-CT improves the speed and precision of scans. Furthermore, it provides detailed anatomical and functional imaging for heart, tumor, and brain investigations across a range of molecular imaging applications.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19151
Which regions are emerging as leaders in the positron emission tomography (pet) nuclear medicine market?
North America was the largest region in the positron emission tomography (PET) nuclear medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (PET) nuclear medicine marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Emission Management Software Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/emission-management-software-global-market-report
Single-Photon Emission Computed Tomography (SPECT) Global Market Report 2024
Emission Monitoring System Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/emission-monitoring-system-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
